Cosmo Pharmaceuticals N.V. (0RGI.L)
CHF 59.0
(-1.5%)
CHF 59.0
(-1.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.14 Million EUR | -78.09% |
| 2022 | 28.05 Million EUR | -15.27% |
| 2021 | 33.11 Million EUR | 1510.6% |
| 2020 | 2.05 Million EUR | 116.71% |
| 2019 | -12.3 Million EUR | 25.96% |
| 2018 | -16.62 Million EUR | -7.26% |
| 2017 | -15.49 Million EUR | -173.77% |
| 2016 | 21 Million EUR | -91.61% |
| 2015 | 250.3 Million EUR | 1026.78% |
| 2014 | 22.21 Million EUR | 71.7% |
| 2013 | 12.93 Million EUR | -51.09% |
| 2012 | 26.45 Million EUR | 166.15% |
| 2011 | 9.94 Million EUR | 83.63% |
| 2010 | 5.41 Million EUR | -5.58% |
| 2009 | 5.73 Million EUR | -54.33% |
| 2008 | 12.55 Million EUR | 5580.09% |
| 2007 | 221 Thousand EUR | 113.9% |
| 2006 | -1.59 Million EUR | -198.82% |
| 2005 | 1.6 Million EUR | 372.25% |
| 2004 | -591 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 43.47 Million EUR | 9000.1% |
| 2024 Q2 | 43.47 Million EUR | 0.0% |
| 2023 Q2 | 3.56 Million EUR | 0.0% |
| 2023 Q3 | -488.5 Thousand EUR | -113.72% |
| 2023 FY | 6.14 Million EUR | -78.09% |
| 2023 Q4 | -488.5 Thousand EUR | 0.0% |
| 2023 Q1 | 3.56 Million EUR | -64.29% |
| 2022 Q3 | 9.97 Million EUR | 146.04% |
| 2022 Q1 | 4.05 Million EUR | -26.91% |
| 2022 FY | 28.05 Million EUR | -15.27% |
| 2022 Q4 | 9.97 Million EUR | 0.0% |
| 2022 Q2 | 4.05 Million EUR | 0.0% |
| 2021 FY | 33.11 Million EUR | 1510.6% |
| 2021 Q2 | 4000.00 EUR | 0.0% |
| 2021 Q1 | 4000.00 EUR | -99.82% |
| 2021 Q3 | 5.54 Million EUR | 138562.5% |
| 2021 Q4 | 5.54 Million EUR | 0.0% |
| 2020 Q1 | -1.31 Million EUR | -153.9% |
| 2020 Q4 | 2.22 Million EUR | 0.0% |
| 2020 FY | 2.05 Million EUR | 116.71% |
| 2020 Q3 | 2.22 Million EUR | 268.42% |
| 2020 Q2 | -1.31 Million EUR | 0.0% |
| 2019 Q2 | -8.6 Million EUR | 0.0% |
| 2019 Q3 | 2.44 Million EUR | 128.45% |
| 2019 FY | -12.3 Million EUR | 25.96% |
| 2019 Q1 | -8.6 Million EUR | -82.79% |
| 2019 Q4 | 2.44 Million EUR | 0.0% |
| 2018 Q3 | -4.7 Million EUR | -30.5% |
| 2018 FY | -16.62 Million EUR | -7.26% |
| 2018 Q2 | -3.6 Million EUR | 0.0% |
| 2018 Q1 | -3.6 Million EUR | -36.44% |
| 2018 Q4 | -4.7 Million EUR | 0.0% |
| 2017 Q3 | -2.64 Million EUR | -22.37% |
| 2017 FY | -15.49 Million EUR | -173.77% |
| 2017 Q4 | -2.64 Million EUR | 0.0% |
| 2017 Q2 | -2.15 Million EUR | 0.0% |
| 2017 Q1 | -2.15 Million EUR | -132.84% |
| 2016 Q1 | 6.12 Million EUR | -32.21% |
| 2016 FY | 21 Million EUR | -91.61% |
| 2016 Q4 | 6.57 Million EUR | 0.0% |
| 2016 Q3 | 6.57 Million EUR | 7.37% |
| 2016 Q2 | 6.12 Million EUR | 0.0% |
| 2015 Q3 | 9.03 Million EUR | 176.88% |
| 2015 Q4 | 9.03 Million EUR | 0.0% |
| 2015 Q1 | -11.75 Million EUR | -408.84% |
| 2015 FY | 250.3 Million EUR | 1026.78% |
| 2015 Q2 | -11.75 Million EUR | 0.0% |
| 2014 FY | 22.21 Million EUR | 71.7% |
| 2014 Q4 | 3.8 Million EUR | 0.0% |
| 2014 Q3 | 3.8 Million EUR | -47.9% |
| 2014 Q1 | 7.3 Million EUR | 133.83% |
| 2014 Q2 | 7.3 Million EUR | 0.0% |
| 2013 Q1 | 3.34 Million EUR | 396.44% |
| 2013 Q2 | 3.34 Million EUR | 0.0% |
| 2013 Q3 | 3.12 Million EUR | -6.66% |
| 2013 Q4 | 3.12 Million EUR | 0.0% |
| 2013 FY | 12.93 Million EUR | -51.09% |
| 2012 FY | 26.45 Million EUR | 166.15% |
| 2012 Q1 | 6.86 Million EUR | 0.0% |
| 2012 Q2 | 6.86 Million EUR | 0.0% |
| 2012 Q4 | 674 Thousand EUR | 0.0% |
| 2012 Q3 | 674 Thousand EUR | -90.18% |
| 2011 Q4 | 6.86 Million EUR | 176.32% |
| 2011 FY | 9.94 Million EUR | 83.63% |
| 2011 Q2 | 2.48 Million EUR | 0.0% |
| 2011 Q1 | 2.48 Million EUR | 0.0% |
| 2011 Q3 | 2.48 Million EUR | 0.0% |
| 2010 Q4 | 2.48 Million EUR | 83.63% |
| 2010 FY | 5.41 Million EUR | -5.58% |
| 2010 Q3 | 1.35 Million EUR | 0.0% |
| 2010 Q2 | 1.35 Million EUR | 0.0% |
| 2010 Q1 | 1.35 Million EUR | 0.0% |
| 2009 Q2 | 1.43 Million EUR | 0.0% |
| 2009 Q4 | 1.35 Million EUR | -5.58% |
| 2009 Q3 | 1.43 Million EUR | 0.0% |
| 2009 FY | 5.73 Million EUR | -54.33% |
| 2009 Q1 | 1.43 Million EUR | 0.0% |
| 2008 Q2 | 3.13 Million EUR | 0.0% |
| 2008 Q1 | 3.13 Million EUR | 0.0% |
| 2008 FY | 12.55 Million EUR | 5580.09% |
| 2008 Q4 | 1.43 Million EUR | -54.33% |
| 2008 Q3 | 3.13 Million EUR | 0.0% |
| 2007 Q4 | 3.13 Million EUR | 8104.58% |
| 2007 Q3 | 38.25 Thousand EUR | 0.0% |
| 2007 Q2 | 38.25 Thousand EUR | 0.0% |
| 2007 Q1 | 38.25 Thousand EUR | 0.0% |
| 2007 FY | 221 Thousand EUR | 113.9% |
| 2006 FY | -1.59 Million EUR | -198.82% |
| 2006 Q1 | 414.75 Thousand EUR | 0.0% |
| 2006 Q4 | 38.25 Thousand EUR | -90.78% |
| 2006 Q2 | 414.75 Thousand EUR | 0.0% |
| 2006 Q3 | 414.75 Thousand EUR | 0.0% |
| 2005 Q2 | 520.25 Thousand EUR | 0.0% |
| 2005 Q3 | 520.25 Thousand EUR | 0.0% |
| 2005 Q4 | 414.75 Thousand EUR | -20.28% |
| 2005 FY | 1.6 Million EUR | 372.25% |
| 2005 Q1 | 520.25 Thousand EUR | 0.0% |
| 2004 Q4 | 520.25 Thousand EUR | 452.12% |
| 2004 FY | -591 Thousand EUR | 0.0% |
| 2004 Q2 | -147.75 Thousand EUR | 0.0% |
| 2004 Q1 | -147.75 Thousand EUR | 0.0% |
| 2004 Q3 | -147.75 Thousand EUR | 0.0% |
| 2003 Q4 | -147.75 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Relief Therapeutics Holding AG | -110.82 Million CHF | 105.546% |
| Tecan Group AG | 135.96 Million CHF | 95.48% |
| Santhera Pharmaceuticals Holding AG | 68.84 Million CHF | 91.073% |
| Basilea Pharmaceutica AG | 19.2 Million CHF | 67.998% |
| Bachem Holding AG | 129.38 Million CHF | 95.25% |
| Siegfried Holding AG | 172.06 Million CHF | 96.428% |
| Molecular Partners AG | -61.1 Million CHF | 110.058% |